
Carlsmed announced the successful completion of the first aprevo cervical procedure. aprevo devices are designed to match the unique anatomical and alignment needs of each patient through Carlsmed’s proprietary AI-powered surgical planning platform and digital production system.
Carlsmed was granted Breakthrough Device designation for aprevo cervical by FDA in 2023 and expects a U.S. commercial launch in 2026.
“On the heels of our IPO, this first cervical procedure represents an exciting milestone as we expand our personalized surgical solutions to the cervical spine,” said Mike Cordonnier, Chairman and CEO of Carlsmed. “We are proud to partner with Dr. Osorio and UCSD Health to bring this breakthrough technology to patients. Our goal is to reduce the need for revision surgeries, improve outcomes, and enhance value across the healthcare system as we work toward establishing a new standard of care.”
Source: Carlsmed
Carlsmed announced the successful completion of the first aprevo cervical procedure. aprevo devices are designed to match the unique anatomical and alignment needs of each patient through Carlsmed’s proprietary AI-powered surgical planning platform and digital production system.
Carlsmed was granted Breakthrough Device designation for...
Carlsmed announced the successful completion of the first aprevo cervical procedure. aprevo devices are designed to match the unique anatomical and alignment needs of each patient through Carlsmed’s proprietary AI-powered surgical planning platform and digital production system.
Carlsmed was granted Breakthrough Device designation for aprevo cervical by FDA in 2023 and expects a U.S. commercial launch in 2026.
“On the heels of our IPO, this first cervical procedure represents an exciting milestone as we expand our personalized surgical solutions to the cervical spine,” said Mike Cordonnier, Chairman and CEO of Carlsmed. “We are proud to partner with Dr. Osorio and UCSD Health to bring this breakthrough technology to patients. Our goal is to reduce the need for revision surgeries, improve outcomes, and enhance value across the healthcare system as we work toward establishing a new standard of care.”
Source: Carlsmed
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.





